Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Core Insights - Seres Therapeutics is advancing its live biotherapeutic programs, particularly focusing on SER-155 for immune checkpoint-related enterocolitis and SER-603 for inflammatory bowel disease, with significant clinical data expected in Q2 2026 [1][2][5] Financial Performance - For the full year 2025, Seres reported a net income from continuing operations of $5.7 million, a significant improvement from a net loss of $125.8 million in 2024, primarily due to lower operating expenses and gains from the sale of VOWST [9] - Research and development expenses decreased to $49.1 million in 2025 from $64.6 million in 2024, reflecting cost management efforts [9] - General and administrative expenses also saw a reduction, totaling $39.2 million in 2025 compared to $53.2 million in 2024 [9] Cash Position - As of December 31, 2025, Seres had $45.8 million in cash and cash equivalents, with expectations to fund operations through Q3 2026 [6] Clinical Development - The company is preparing for Phase 2 trials of SER-155 aimed at preventing serious bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant [2][5] - SER-155 is currently involved in an investigator-sponsored trial at Memorial Sloan Kettering Cancer Center, with enrollment completed and clinical data anticipated in Q2 2026 [2][5] Strategic Focus - Seres is actively seeking partnerships and funding to support the advancement of its pipeline programs, indicating a strategic focus on collaboration to enhance resource availability [3][5]